Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial.

A pre-planned sensitivity analysis of OS of the QuANTUM-First trial that censored at the starting date of the conditioning regimen for allo-HCT revealed a strong trend favoring quizartinib over placebo (HR=0.75), consistent with the primary analysis of OS (HR=0.78). 19 RFS and CIR curves revealed that quizartinib provided higher RFS rates and lower CIR rates versus placebo, regardless of whether patients underwent allo-HCT or not, which could be attributed to hig

also in 5,725 other papers